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ABSTRACT 
Background: Fatigue is commonly reported by cancer patients. In some instances it can persist after treatment is com-
pleted. In order to develop effective treatment strategies it is important to understand the mechanisms underlying the 
development of fatigue and to be able to predict those that may be at greatest risk of experiencing fatigue during and 
following treatment. The current paper examines predisposing factors for fatigue including altered fatty acid homeosta-
sis in a cohort of breast cancer radiotherapy patients. Methodology: Patients had undergone breast-conserving surgery 
and adjuvant breast irradiation. Prior to radiotherapy the patients were free from significant fatigue. Levels of fatigue 
were determined prior to and following radiotherapy using the Functional Assessment of Cancer Therapy fatigue sub-
scale. Plasma fatty acid levels, urinary and plasma amino acid levels, blood biochemistry factors and general health and 
lifestyle characteristics were assessed. Results: Following radiotherapy, significant fatigue affected approximately one 
third of the 26 patients and these subjects were then assigned to the fatigued cohort. Univariate analysis revealed that 
higher levels of the fatty acids myristic acid and eicosadienoic acid were present for the fatigued cohort prior to radio-
therapy. Multivariate analysis also revealed that fatty acid homeostasis was altered between the fatigued and 
non-fatigued groups at baseline. Orthogonal partial least squares discriminant analysis of the general health, lifestyle 
and metabolic data revealed that the fatigued and non-fatigued patients could be clustered into two clearly separate 
groups. Conclusions: The results supported the proposition that the fatigued patients had an underlying metabolic ho-
meostasis which may predispose them to the development of fatigue. Biochemical and general health profiling of breast 
cancer patients has the potential to identify those at most risk of developing significant fatigue following radiotherapy. 
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1. Introduction 
With the development of improved methods for the 
screening and treatment of breast cancer and subsequent 
increased survival rates [1] there is a growing need to 
consider quality of life after treatment is completed. Fa-
tigue is the most common symptom experienced by can-
cer patients. It can result in a reduction in quality of life 
both during therapy [2] and in some cases persist long 
after treatment has been completed [3,4]. Although its 
etiology remains unknown a number of therapies have 
been trialed for cancer-related fatigue including exercise 
programs [5] and various psychosocial interventions [6]. 
Not all breast cancer patients receiving radiotherapy will 
develop fatigue and to date it has not been possible to 
predict which patients would develop significant fatigue 
following treatment and which would remain fatigue-free. 
It has been proposed that cancer-related fatigue is multi-
factorial in origin with biological, psychological and so-
cial factors contributing to its development [6]. Profiling 
may provide an opportunity to further understand the 
etiology of cancer-related fatigue and to potentially de-
velop a predictive method to identify those patients most 
at risk of developing significant fatigue. The ability to 
identify patients at risk of developing fatigue would al-
low clinicians to target therapies for fatigue at this sub-
group. Through patient profiling it may be possible to not 
only prevent the development of fatigue but also to iden-
tify particular risk factors which are amenable to treat-
ment. The formulation of an amino acid nutritional sup-
plement aimed at addressing possible nutritional defi-
ciencies may prove to be one such treatment. The current 
study aimed to determine whether alterations in underly-
ing fatty acid metabolism could be identified in breast 
cancer radiotherapy patients who developed significant *Corresponding author. 
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fatigue following treatment compared with those patients 
who remained fatigue-free. The study also aimed to de-
termine whether patient profiling incorporating a range 
of variables including metabolic and general health and 
lifestyle characteristics, would allow for the differentia-
tion of fatigued and non-fatigued patient groups. 
2. Materials and Methods 
2.1. Patient Characteristics and Measures 
Study participants included twenty-six women (age, 55.6 
± 7.7 years, mean ± SD) who underwent breast-con- 
serving surgery for breast cancer followed by adjuvant 
breast irradiation. Patients were assessed for levels of 
fatigue using the FACT fatigue subscale [7]. Patients 
were also assessed for anxiety and depression and nu-
merous general health and lifestyle characteristics. Blood 
and urine samples were collected for blood biochemistry, 
plasma fatty acid, plasma amino acid and urinary amino 
acid analysis. With the exception of plasma fatty acids, 
the methodology and results for these measures have 
previously been presented for a subgroup of the current 
patient cohort see [8]. It should be noted that as a large 
number of subject characteristics were assessed, in some 
instances missing data resulted in varying sample num-
bers. The study was a pilot study and the interpretation of 
the results should be undertaken with this in mind. The 
study protocol was approved by the Hunter Area Re-
search Ethics Committee and all subjects provided in-
formed consent. 
2.2. Plasma Lipid Fatty Acid Analysis 
Blood samples were collected from patients at baseline 
(immediately prior to commencement of a radiotherapy 
treatment regime), at 5 weeks and at 6 months after 
commencement of radiotherapy. Thirty-five mL venous 
blood samples were collected from each patient at the 
Radiation Treatment Department, Calvary Mater New-
castle for blood biochemistry, plasma amino acid and 
plasma fatty acid analysis. Each patient had fasted ap-
proximately 10 hours prior to sample collection. Lithium 
heparin plasma separation tubes were used for the collec-
tion of blood samples for plasma fatty acids. Samples 
were spun at 3000 rpm for 10 min, frozen within an hour 
of collection and then stored at −80˚C. Samples were 
transported to the University of Newcastle laboratory 
where they were stored at −20˚C until processing. Fatty 
acid composition of plasma lipids was then determined 
via gas chromatography-mass spectrometry (GC-MS). 
Prior to GC-MS detection, plasma lipids were converted 
to fatty acid methyl esters (FAMEs) through a trans-
esterification method developed by Lepage and Roy [9]. 
2.3. Statistical Analysis 
Univariate analyses and forward stepwise discriminant 
analysis were performed using the Statsoft Statistica™ 
(release 6.0) software. Fatty acid data were assessed us- 
ing forward stepwise discriminant function analysis per- 
formed on log transformed fatty acid concentration data. 
Associations between altered blood biochemistry factors 
and fatty acid concentration data were performed using 
Spearman rank order correlation analysis. Mann-Whitney 
U test, Chi square and Fisher’s exact probability were 
also used where appropriate. 
Orthogonal partial least squares discriminant analysis 
(OPLS-DA) was conducted using SIMCA-P+ (12.0, 
Umetrics Sweden) [10,11]. Plasma and urinary amino 
acid data and blood biochemistry data were log trans- 
formed prior to OPLS analysis. All data were pre-treated 
by mean centering and unit variance scaling prior to 
model generation. Optimal model complexity was pro- 
duced according to the cross validation procedure [12]. 
All analyses were performed using seven cross validation 
groups in which all data were left out of the modeling 
once. As recommended, the assignment of cross-valida- 
tion groups was implemented by SIMCA-P+. Data were 
checked for outliers using Hotelling’s T2 and each indi- 
vidual calculated orthogonal score distance to the mod- 
eled X-data, and all observations were found to be well 
within the 95% confidence interval. 
3. Results and Discussion 
Patient data were included in this analysis if they did not 
report significant fatigue at the commencement of the 
radiotherapy treatment regime. To determine this, a sub- 
set of the FACT fatigue scale [7] consisting of 13 ques- 
tions was used prior to commencement of radiotherapy 
treatment to assess baseline levels of the fatigue in the 
patients. In this study and previous research, significant 
fatigue was defined as a score of <37 [13,14]. Patients 
were included in the present study if they had a score of 
≥37 at the baseline sampling point just prior to com- 
mencement of radiotherapy. The patients were then sub- 
sequently classified within the fatigued group (n = 9) if 
they scored <37 at the 5-week and/or 6-month assess- 
ments. The non-fatigued group (n = 17) scored ≥ 37 at 
each follow-up assessment. Approximately one third of 
the patient cohort developed significant fatigue following 
radiotherapy (Table 1). As expected, significantly lower 
mean fatigue scores for the fatigued group were seen at 5 
weeks (mean ± SEM, fatigued 34.8 ± 2.7, non-fatigued 
48.2 ± 1.1, P < 0.0001) and at the 6 month mark (fa-
tigued 36.0 ± 4.3, non-fatigued 51.5 ± 0.8, P < 0.0001). 
Despite the exclusion of subjects reporting significant 
fatigue prior to commencement of radiotherapy, a sig-
nificant difference was observed at baseline between the  
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Table 1. Patient characteristics including age, body mass 
index, menopausal status and radiation dosage for the en- 
tire study cohort, the fatigued and non-fatigued groups. 
Characteristic Entire  group 
Fatigued 
group 
Non-fatigued 
group 
Number 26 9 17 
Age (years, mean ± SD)* 
Age range 
55.6 ± 7.7 
39.8 - 71.8 
55.1 ± 7.1 
39.8 - 63.2 
55.8 ± 8.3 
42.0 - 71.8
Body mass index  
(mean ± SD)* 27.5 ± 5.2 28.7 ± 6.2 26.9 ± 4.6 
Postmenopausal (n)* 12 5 7 
Whole-breast radiation 
dose (Gy) 50 50 50 
Boost dose (Gy) (n)* 10 (9) 10 (3) 10 (6) 
Laterality of primary 
tumor  
(percentage right breast)* 
57.7% 44.4% 64.7% 
Statistical tests: ANOVA, Chi square and Fisher’s exact probability were 
used as appropriate. *None of the comparisons revealed statistically signifi-
cant differences between fatigued and non-fatigued study groups (P < 0.05). 
 
mean fatigue scores of the two groups (mean ± SEM, 
fatigued 46.2 ± 2.2, non-fatigued 51.7 ± 0.8, n = 9 and 17, 
P < 0.01). Pre-treatment levels of fatigue have previously 
been demonstrated to predict the levels of fatigue re-
ported following radiotherapy for cancer [15]. In the 
current study, no significant differences were revealed 
between the fatigued and non-fatigued patient character-
istics (age, BMI, menopausal status and radiation dosage 
(Table 1). 
With only one exception, systemic hormone therapy, 
no significant differences were revealed between the fa-
tigued and non-fatigued groups in the many clinical or 
general health and lifestyle characteristics assessed [8] 
(for a list of measures undertaken, see [8]). In addition to 
these factors, other confounding variables such as differ-
ing treatment interventions, types and stages of cancer 
and the presence of fatigue prior to radiation therapy 
were also controlled. Therefore it proved possible in the 
current project to investigate the onset of fatigue follow-
ing radiotherapy treatment with a relatively homogenous 
subject cohort. 
Blood plasma amino acids and urinary amino acids 
were previously assessed for a subset of the current pa-
tient cohort and these data have been summarized, see 
[8]. The fatty acid levels were also assessed for the same 
blood plasma samples and the results have been pre-
sented for the baseline, 5-week and 6-month sampling 
points in Table 2. 
In general, the fatigued group had higher levels of 
saturated fatty acids (SFA), monounsaturated fatty acids 
(MUFA), polyunsaturated fatty acids (PUFA) and total 
fatty acids compared with the non-fatigued group at 
baseline. However, the differences seen in these classes 
of fatty acids did not reach levels of statistical signifi-
cance due to higher than anticipated variance. Two ex-
ceptions to this were myristic acid (C14:0) and eicosadi-
enoic acid (C20:2n-6) which were significantly elevated 
for the fatigued group compared with the non-fatigued 
group at baseline (Table 2). 
The data for the baseline fatty acid data were analyzed 
by forward stepwise discriminant function analysis which 
indicated a significant difference in the fatty acid profiles 
of the fatigued group compared with the non-fatigued 
group (Wilks’ Lambda = 0.4, P < 0.002). The discrimi- 
nant function model was able to accurately classify the 
participants of the study into their appropriate clinical 
groups with 75% of the fatigue group correctly classified 
and 94% of the non-fatigued group (total accuracy, 
88%). 
Blood biochemistry analyses (electrolyte levels, kid- 
ney, liver and thyroid function tests) were carried out for 
each of the three time points. Univariate analysis (Mann- 
Whitney U test) revealed that alkaline phosphatase was 
reduced at baseline and after 5 weeks of radiotherapy for 
the fatigued cohort in comparison to the fatigue-free 
group. Anion gap was reduced at 5 weeks while total 
protein levels were reduced at 6 months for the fatigued 
cohort, see [8]. Fatty acid data were subjected to correla- 
tion analyses with two of these significantly altered 
blood biochemistry factors, total protein and alkaline 
phosphatase. Correlation analyses were performed against 
all fatty acids measured and for each sampling time (see 
Figures 1 and 2). The r-values have been plotted for each 
of the fatty acids which have been grouped according to 
their fatty acid classes (SFA, MUFA and PUFA) to show 
positive and negative associations. The correlations dis- 
cussed were significant at the P < 0.05 level. It would be 
expected that if metabolic homeostasis was not affected 
in the fatigued group compared with the non-fatigued 
group, then no differences in correlation patterns would 
be evident. Figure 1(a) shows that in the non-fatigued 
group all the fatty acids had positive associations with 
the total plasma protein concentrations. A large number 
of the fatty acids (C16:0, C18:0, C22:0, C16:1n-7, 
C18:1n-7, C18:1n-9, C20:1n-9, C24:1n-9 and C20:4n-6), 
and the fatty acid classes (total SFA, total MUFA and 
total fatty acids) showed significant positive correlations 
(P < 0.05) for the non-fatigued group. In contrast, the 
fatigued group showed none of the above correlations but 
did have C18:2n-6, total n-6 and total PUFA as signifi-
cant positive correlations with total plasma protein. 
Many of the associations observed in the fatigue group 
were negative but not significant at the baseline assess-
ment. These results indicated that different associations 
were present between the plasma fatty acid composition 
and plasma protein concentrations for the fatigued group 
compared with the non-fatigued group. 
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Table 2. The concentrations of blood plasma fatty acids in the fatigued and non-fatigued groups at the commencement of 
radiotherapy (baseline), completion of radiotherapy (5-week) and at 6-months after the baseline assessment. 
Plasma fatty acid Baseline nmol/mL, mean (SEM) 
5 weeks 
nmol/mL, mean (SEM) 
6 months 
nmol/mL, mean (SEM) 
 Fatigued Non-fatigued Fatigued Non-fatigued Fatigued Non-fatigued 
Saturated       
Myristic acid (14:0) 338.9 (27.2)* 266.1 (22.9*) 289.3 (40.8) 319.3 (28.5) 332.9 (38.4) 294.8 (22.5) 
Palmitic acid (16:0) 22324.0 (1625.8) 15837.1 (2470.6) 18965.0 (2430.0) 19777.0 (2664.3) 18813.9 (4212.7) 14081 (2691.1)
Stearic acid (18:0) 3,932.8 (124.5) 3111.4 (364.3) 3541.8 (311.5) 3543.4 (345.0) 3361.3 (514.5) 2911.4 (401.8) 
Arachidic acid (20:0) 107.4 (5.6) 92.1 (7.2) 100.1 (7.7) 105.1 (7.4) 104.5 (8.6) 92.2 (6.8) 
Behenic acid (22:0) 306.6 (15.2) 268.3 (28.4) 251.8 (32.0) 281.4 (20.3 274.6 (23.1) 258.3 (23.0) 
Lignoceric acid (24:0) 291.7 (20.5) 273.8 (29.4) 265.0 (15.7) 281.4 (21.2) 261.1 (24.0) 261.8 (25.5) 
Total SFA 27301.3 (1742.8) 19848.7 (2877.7) 23413.0 (2747.9) 24307.6 (3019.1) 23148.2 (4768.2) 17899.7 (3122.9)
Monounsaturated       
Palmitoleic acid 
(16:1n-7) 1537.6 (219.5) 1271.3 (156.4) 1218.9 (187.1) 1530.8 (164.6) 1448.8 (210.1) 1203.1 (153.2) 
cis-Vaccenic acid 
(18:1n-7) 1194.7 (103.9) 983.0 (116.9) 1004.7 (73.0) 1207.9 (143.4) 1069.6 (180.6) 872.2 (144.2) 
Oleic acid (18:1n-9) 24637.8 (2161.1) 18940.5 (3276.8) 20800.4 (2756.2) 23442.8 (3589.5) 22412.5 (5250.3) 16831.6 (3572.8)
Gondoic acid (20:1n-9) 143.7 (6.2) 146.6 (7.1) 147.5 (3.4) 152.3 (5.9) 150.9 (7.2) 143.3 (7.3) 
Erucic acid (22:1n-9) 167.0 (25.2) 149.7 (20.5) 183.1 (23.9) 178.4 (25.2) 107.7 (17.4) 114.5 (16.4) 
Nervonic acid 
(24:1n-9) 1062.7 (56.5) 867.3 (116.7) 975.1 (92.0) 986.6 (99.2) 874.2 (109.7) 810.0 (109.2) 
Total MUFA 28743.4 (2437.3) 22358.5 (3603.0) 24329.6 (3018.6) 27498.9 (3911.3) 26063.7 (5683.6) 19974.6 (3947.4)
Polyunsaturated       
n – 6       
Linoleic acid (18:2n-6) 20971.3 (1049.7) 15650.9 (2350.3) 18581.2 (1358.9) 17,802.6 (2432.1) 15,698.8 (3233.7) 13369.1 (2337.5)
Arachidonic acid  
(20:4n-6) 5913.7 (496.8) 4468.5 (631.1) 5255.1 (500.5) 5,416.9 (672.1) 4,705.6 (896.5) 3927.5 (605.5) 
Eicosadienoic acid 
(20:2n-6) 100.0 (3.2)
** 77.6 (7.4)** 92.6 (4.7) 89.3 (6.7) 84.0 (7.1) 80.5 (7.1) 
Total n-6 26,985.0 (1276.0) 20197.1 (2954.5) 23865.9 (1721.7) 23,308.7 (2996.5) 20,488.3 (4016.8) 17377.1 (2917.7)
n-3       
Eicosapentaenoic acid 
(20:5n-3) 970.0 (145.3) 860.5 (158.1) 821.0 (117.8) 958.9 (159.5) 772.7 (141.5) 739.7 (89.0) 
Docosahexaenoic acid 
(22:6n-3) 1983.1 (240.8) 1478.2 (189.3) 1906.8 (227.9) 1,774.9 (187.3) 1,888.7 (375.0) 1564.0 (226.8) 
Total n-3 2953.1 (373.9) 2338.7 (341.0) 2727.8 (331.0) 2,733.7 (332.5) 2,661.4 (510.5) 2303.7 (303.8) 
Total PUFA 29938.0 (1278.8) 22535.8 (3205.2) 26593.7 (1805.3) 26,042 (3192.9) 23,149.7 (4434.4) 19680.8 (3162.1)
Total Fatty Acids 85982.8 (4451.5) 64743.0 (9500.2) 74336.3 (7083.0) 77,848.9 (9938.2) 72,361.7 (14724.0) 57555.1 (10018.6)
Statistical test: Mann-Whitney U test, P < 0.04* and P < 0.02**. Values are the mean (SEM) and are expressed as fatty acid concentration (nmol/mL). n = 8 and 
17 at baseline, 9 and 16 at 5 weeks and 9 and 17 at 6 months for the fatigued and non-fatigued groups respectively. 
 
Following five weeks of radiation treatment all fatty 
acid associations with total plasma protein were positive 
for the non-fatigued group, although only those for C22:0, 
C24:0, C24:1n-9, C18:2n-6, total n-6, total n-3, total 
PUFA and total fatty acids were statistically significant 
(P < 0.05) (Figure 1(b)). In comparison to the  
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Figure 1. Correlations between total protein (g/L) and plasma fatty acids (nmol/mL) at each of the clinical assessment times, 
(a) Baseline; (b) 5 weeks and (c) 6 Months, for the fatigued and non-fatigued patient groups. 
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associations demonstrated at baseline, the pattern seen at 
5 weeks represented a changing profile of associations 
for the non-fatigued cohort following radiotherapy. In 
contrast, the fatigued group showed predominantly nega-
tive and non-significant associations between plasma 
fatty acid concentrations and total protein levels at 5 
weeks. 
At the 6 month sampling point, with only one excep-
tion, the non-fatigued group displayed negative correla-
tions between the plasma fatty acids and total protein, 
none of which were significant. However, all the fatty 
acids for the fatigued group displayed positive associa-
tions. The fatty acids C18:0, C20:0, C22:0, C24:0, 
C20:1n-9, C22:1n-9, C24:1n-9, C18:2n-6, total n-6 and 
total PUFA all displayed strong, significant correlations 
with total protein. It was clear that the correlations be-
tween total protein levels and plasma fatty acid concen-
trations changed over the course of the study for both 
groups. The profiles of associations were different be-
tween the fatigued groups and non-fatigued groups at all 
stages of assessment. 
A second set of correlational analyses was based upon 
alkaline phosphatase activities and plasma fatty acids. In 
contrast to total protein, alkaline phosphatase was not 
correlated with any of the fatty acids measured for the 
non-fatigued or fatigued groups at baseline (Figure 2(a)). 
At 5 weeks (Figure 2(b)), alkaline phosphatase was neg- 
atively correlated with both C22:6n-3 and total n-3 fatty 
acids for the non-fatigued group. The fatigued group 
showed a single significant correlation between alkaline 
phosphatase and C14:0. The 6-month assessment (Fig- 
ure 2(c)) showed no associations between alkaline phos-
phatase and plasma fatty acids for the non-fatigued group 
while the fatigued group comprised many strong positive 
correlations including with C16:0, C16:1n-7, C18:2n-6, 
C18:1n-9, C18:1n-7, C18:0, C20:4n-6, C22:6n-3, C24: 
1n-9, total fatty acids, total MUFA, total PUFA, total n-3 
and total n-6 (P < 0.05). 
The entire dataset consisting of clinical symptoms, life 
style characteristics, blood biochemistry, blood plasma 
amino acids and fatty acids as well as urinary excretion 
of amino acids were collated for each patient and sub-
jected to orthogonal partial least squares (OPLS) dis-
criminant analysis. Inspection of the OPLS scores re-
vealed that fatigued patients and the non-fatigued pa-
tients could be effectively separated and clustered into 
two clearly defined groups (Figure 3). This finding sup-
ported the proposition that the fatigued patients had an 
underlying metabolism which made them susceptible to 
developing severe fatigue following radiotherapy. The 
patients who were assigned to the fatigued group have 
been coded in red and are clustered on the right hand side 
with higher t1 scores. It is possible to see that the two 
repeat visits at 5 weeks and 6 months, also occurred 
within the same cluster compared with the non-fatigued 
patients who were positioned on the left-hand side with 
negative t1 scores. 
The OPLS-DA revealed the existence of a number of 
components contributing to the reported development of 
significant fatigue following radiation treatment. A pri- 
mary set of these differential variables have been pre- 
sented in Table 3 and include biochemical, clinical and 
general health and lifestyle measures. 
The components contributing to the OPLS-DA sepa- 
ration of fatigued and non-fatigued patients included 
numerous biochemical measures, the identification of 
which supported the univariate analyses previously per- 
formed for this group of patients. An increase in the ex- 
cretion of urinary amino acids was seen for the fatigued 
group in comparison to the non-fatigued group whilst 
alkaline phosphatase, total protein and anion gap demon- 
strated significant differences between the two groups, 
see [8].  
An overall pattern of increased excretion of urinary 
amino acids was supported by the OPLS-components 
from the DA model. The presence of a differing fatty 
acid homeostasis and alterations in blood biochemistry 
factors including in alkaline phosphatase activity were 
also supported by the P1 loadings. Amongst the general 
health and lifestyle factors contributing to the OPLS-DA 
separation were factors which have previously been as-
sociated with cancer related fatigue such as anxiety [16], 
depression [17,18], systemic hormone therapy [19] and 
the presence of comorbid diseases such as arthritis [18]. 
The identification of other contributing factors in the 
development of fatigue in breast cancer patients such as 
tea, coffee and red wine consumption and the laterality of 
the primary tumor may warrant further investigation. It 
has been suggested that due to incidental cardiac irradia-
tion, the risk of development of cardiovascular disease 
(CVD) in breast cancer survivors may be influenced by 
the laterality of the tumor. Amongst older women, an 
increase in the risk for CVD has been demonstrated for 
breast cancer survivors who had received radiotherapy 
treatment for left-sided tumors [20]. In the current study, 
both primary tumor laterality (left-side) and CVD were 
principal factors contributing to the separation of the 
fatigued and non-fatigued patients. 
4. Conclusion 
Alterations in metabolic homeostasis between the fa-
tigued and the non-fatigued groups prior to and following 
radiotherapy were indicated by both univariate and cor-
relational analyses of the fatty acid data. Forward step-
wise discriminant function analyses at baseline also in-
dicated that alterations in fatty acid homeostasis were 
present before radiotherapy treatment was begun for the 
fatigued cohort. In concert with the results of amino acid  
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Figure 2. Correlations between alkaline phosphatase (U/L) and plasma fatty acids (nmol/mL) at each of the clinical assess- 
ment times, (a) Baseline; (b) 5 weeks and (c) 6 Months, for the fatigued and non-fatigued patient groups. 
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Table 3. Parameters contributing to the OPLS-DA separation of patient groups: Characteristics of patients who developed 
fatigue following radiotherapy compared with the non-fatigued cohort. 
Health and lifestyle 
 Less likely to report menopausal status as perimenopausal 
or status unknown 
 Less likely to be taking antihypertensive medication 
baseline 
 Less likely to be taking lipid lowering medication at 
baseline 
 Shorter distances travelled to treatment 
 Laterality of primary tumor less likely to be on right-side 
 Drinking less tea (cups/day) 
 Less likely to have undergone major surgery in previous 6 
months 
 Drinking less coffee (cups/day) 
 Less likely to have a diagnosis of coronary vascular disease
 Less likely to report marital status as married 
 
 Higher HADS Depression score 
 More hours worked per week 
 More likely to be taking medications (other than aspirin/NSAI,  
corticosteroid, antihypertensive, antiangina, lipid lowering, anticoagulin, 
hormone)  
 More likely to have a history of previous major surgery 
 More likely to be a drinker of red wine 
 More likely to report marital status as single—never married 
 More likely to report a previous/current significant infectious disease 
and recovery 
 More likely to be receiving systemic hormone therapy (tamoxifen or 
Arimidex) 
 More likely to be receiving systemic hormone therapy 
post-radiotherapy 
 Higher HADS Anxiety score 
 More likely to be a coffee drinker 
 Laterality of primary tumor more likely to be on left-side 
 More likely to report a diagnosis of arthritis 
 More likely to report diagnosis with other major disease/s 
 More likely to be working 
 More likely to report menopausal status as pre-menopausal 
 More likely to be a tea drinker 
 
Biochemical measures 
Reduced measures Increased measures 
Plasma components: 
 Alkaline phosphatase (U/L) 
 Tyrosine  
 Total protein (g/L) 
 Anion gap (mmol/L) 
 Lysine 
 C20:5n-3 (%) 
 C20:1n-9 (%) 
 Calculated globulin (g/L) 
 C16:1n-7 (%) 
 C24:0 (%) 
 Aspartic acid 
 C14:0 (%) 
 C22:0 (%) 
 Thyroid stimulating hormone (mU/L) 
 C22:1n-9 (%) 
 C18:0 (%) 
Plasma components: 
 Chloride (mmol/L) 
 C16:0 (%) 
Urinary components (concentration): 
 Alanine 
 Glutamine 
 Threonine 
 Proline 
 Histidine 
 Glycine 
 Phenylalanine 
 Asparagine 
 Serine 
 Valine 
 Tryptophan 
 Glutamic acid 
 Leucine 
 Alpha-aminoadipic acid 
 Tyrosine  
 Cystine  
 Isoleucine  
 Proline-hydroxyproline 
 Alpha-aminobutyric acid 
 Methionine 
  Aspartic acid 
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Figure 3. Orthogonal partial least squares discriminant analysis (OPLS-DA) scores scatter plot showing cluster separation of 
the biochemical, health and lifestyle data of fatigued breast cancer radiotherapy patients from the non-fatigued breast cancer 
radiotherapy patients at all three time points. 
 
analysis carried out for a subgroup of the same patient 
cohort [8] these findings supported the hypothesis that 
the fatigued patients possessed an underlying metabolic 
homeostasis which could contribute to their susceptibility 
for the development of significant fatigue following ra- 
diotherapy. The results indicated that the profiling of 
breast cancer radiotherapy patients, including biochemi- 
cal, health and lifestyle characteristics, has the potential 
to identify those women most at risk of developing sig- 
nificant fatigue. The components included within the 
OPLS-DA model indicated that a number of risk factors 
for fatigue were present within the fatigued cohort in- 
cluding an elevated loss of amino acids via urinary ex- 
cretion. The results generated suggest that the use of 
OPLS-DA modeling has the potential to be used as a 
screening tool to predict the development of significant 
fatigue in breast cancer radiotherapy patients who are 
free from fatigue prior to treatment. A larger scale study 
is required to test the predictive power of the model. 
5. Acknowledgements 
This study was funded by the Judith Mason and Harold 
Stannett Williams Memorial Foundation. We also wish 
to thank Dr. Jane Ludbrook, Dr. Peter O’Brien and Dr. 
Mahesh Kumar for their involvement in the recruitment 
of patients. 
REFERENCES 
[1] A. Maxmen, “The Hard Facts,” Nature, Vol. 485, No. 
7400, 2012, pp. S50-S51. doi:10.1038/485S50a 
[2] P. Stone, A. Richardson, E. Ream, et al., “Cancer-Related 
Fatigue: Inevitable, Unimportant and Untreatable? Re- 
sults of a Multi-Centre Patient Survey,” Annals of On- 
cology, Vol. 11, No. 8, 2000, pp. 971-975.  
doi:10.1023/A:1008318932641 
[3] P. Servaes, M. F. M. Gielissen, S. Verhagen, et al., “The 
Course of Severe Fatigue in Disease-Free Breast Cancer 
Patients: A Longitudinal Study,” Psycho-Oncology, Vol 
16, No. 9, 2007, pp. 787-795. doi:10.1002/pon.1120 
[4] A. C. G. Cavalli Kluthcovsky, A. A. Urbanetz, D. S. de 
Carvalho, et al., “Fatigue after Treatment in Breast Can- 
cer Survivors: Prevalence, Determinants and Impact on 
Health-Related Quality of Life,” Support Care Cancer, 
Vol. 20, No. 8, 2012, pp. 1901-1909.  
doi:10.1007/s00520-011-1293-7 
[5] V. Mock, C. Frangakis, N. E. Davidson, et al., “Exercise 
Manages Fatigue during Breast Cancer Treatment: A 
Randomized Controlled Trial,” Psycho-Oncology, Vol. 14, 
No. 6, 2005, pp. 464-477. doi:10.1002/pon.863 
[6] K. M. Mustian, G. R. Morrow, J. K. Carroll, et al., “Inte- 
grative Nonpharmacologic Behavioral Interventions for 
the Management of Cancer-Related Fatigue,” Oncologist, 
Vol. 12, Suppl. 1, 2007, pp. 52-67.  
doi:10.1634/theoncologist.12-S1-52 
[7] S. B. Yellen, D. F. Cella, K. Webster, et al., “Measuring 
Fatigue and Other Anemia-Related Symptoms with the 
Functional Assessment of Cancer Therapy (FACT) Meas- 
urement System,” Journal of Pain and Symptom Man- 
agement, Vol. 13, No. 2, 1997, pp. 63-74.  
doi:10.1016/S0885-3924(96)00274-6 
[8] R. H. Dunstan, D. L. Sparkes, M. M. Macdonald, et al., 
“Altered Amino Acid Homeostasis and the Development 
of Fatigue by Breast Cancer Radiotherapy Patients: A Pi- 
lot Study,” Clinical Biochemistry, Vol. 44, No. 2-3, 2011, 
pp. 208-215. doi:10.1016/j.clinbiochem.2010.10.002 
[9] G. Lepage and C. C. Roy, “Direct Transesterification of 
All Classes of Lipids in a One-Step Reaction,” The Jour- 
nal of Lipid Research, Vol. 27, No. 1, 1986, pp. 114-120.  
[10] J. Trygg and S. Wold, “Orthogonal Projections to Latent 
Structures (O-PLS),” Journal of Chemometrics, Vol. 16, 
No. 3, 2002, pp. 119-128. doi:10.1002/cem.695 
Metabolic, Health and Lifestyle Profiling of Breast Cancer Radiotherapy Patients and the Risk of Developing Fatigue 740 
[11] J. E. Jackson, “A User’s Guide to Principal Components,” 
Wiley, New York, 1991. doi:10.1002/0471725331 
[12] S. Wold, “Cross-Validatory Estimation of the Number of 
Components in Factor and Principal Components Mod- 
els,” Technometrics, Vol. 20, No. 4, 1978. pp. 397-405.  
doi:10.1080/00401706.1978.10489693 
[13] C. Cleeland and S. Wang, “Measuring and Understanding 
Fatigue,” Oncology, Vol. 13, No. 11A, 1999, pp. 91-97.  
[14] C. Wratten, J. Kilmurray, S. Nash, et al., “Fatigue during 
Breast Radiotherapy and Its Relationship to Biological 
Factors,” International Journal of Radiation Oncology, 
Biology and Physics, Vol. 59, No. 1, 2004, pp. 160-167. 
doi:10.1016/j.ijrobp.2003.10.008 
[15] E. M. A. Smets, M. R. M. Visser, A. F. M. N. Wil-
lems-Groot, et al., “Fatigue and Radiotherapy: (A) Ex- 
perience in Patients Undergoing Treatment,” British 
Journal of Cancer, Vol. 78, No. 7, 1998, pp. 899-906.  
doi:10.1038/bjc.1998.599 
[16] H. Geinitz, F. B. Zimmermann, R. Thamm, et al., “Fa- 
tigue in Patients with Adjuvant Radiation Therapy for 
Breast Cancer: Long-Term Follow-Up,” Journal of Can- 
cer Research and Clinical Oncology, Vol. 130, No. 6, 
2004, pp. 327-333. doi:10.1007/s00432-003-0540-9 
[17] R. Morant, “Asthenia: An Important Symptom in Cancer 
Patients,” Cancer Treatment Reviews, Vol. 22, Suppl. A, 
1996, pp. 117-122. doi:10.1016/S0305-7372(96)90073-0 
[18] J. E. Bower, P. A. Ganz, K. A. Desmond, et al., “Fatigue 
in Breast Cancer Survivors: Occurrence, Correlates, and 
Impact on Quality of Life,” Journal of Clinical Oncology, 
Vol. 18, No. 4, 2000, pp. 743-753.  
[19] S. Haghighat, M. E. Akbari, K. Holakouei, et al., “Factors 
Predicting Fatigue in Breast Cancer Patients,” Support 
Care Cancer, Vol. 11, No. 8, 2003. pp. 533-538.  
doi:10.1007/s00520-003-0473-5 
[20] R. Haque, M. U. Yood, A. M. Geiger, et al., “Long-Term 
Safety of Radiotherapy and Breast Cancer Laterality in 
Older Survivors,” Cancer Epidemiology, Biomarkers & 
Prevention, Vol. 20, No. 10, 2011, pp. 2120-2126. 
doi:10.1158/1055-9965.EPI-11-0348 
 
 
Copyright © 2012 SciRes.                                                                                  JCT 
